From one of my upcoming lectures: ~90% of people living with obesity remain untreated.

🏆 Tirzepatide vs. Semaglutide The heavyweight bout we’ve all been waiting for—and it’s a TKO. - - - A new NEJM study just dropped the first head-to-head trial in people with obesity (no diabetes). Here’s how it played out over 72 weeks: 🥇 Tirzepatide (Zepbound) vs 🥈 Semaglutide (Wegovy) 🔹 –20.2% vs –13.7% weight loss → 47% greater relative reduction 🔹 20% on tirzepatide lost ≥30% of their body weight (triple the semaglutide rate!) 🔹 Waistline: –18.4 cm vs –13.0 cm 🔹 Sex matters: women in both arms lost ~6% more than men 📉 Responder rates (tirzepatide vs semaglutide): ✅ ≥10% loss: 81.6% vs 60.5% ✅ ≥15% loss: 64.6% vs 40.1% ✅ ≥20% loss: 48.4% vs 27.3% ✅ ≥25% loss: 31.6% vs 16.1% ⚠️ Side effects? Mostly GI. Mostly manageable. No new red flags. Bottom line: This isn’t incremental—it’s transformational. GLP-1 was the revolution. Tirzepatide is the next frontier. Let’s talk: Access. Equity. Long-term outcomes. Are formularies ready for this future? 🔗 Full NEJM study: nejm.org/doi/full/10.1056/NE… #Zepbound #Wegovy #Tirzepatide #Semaglutide #ObesityMedicine #GLP1 #GIP #NEJM #WeightLoss #HealthTech #DigitalHealth #MedTwitter h/t @scottisaacsmd for images.

🧵 IS BARIATRIC SURGERY DANGEROUS? Let’s look at the global data. Swipe through for a data-driven breakdown.